# Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

> **NCT04954599** · PHASE1,PHASE2 · RECRUITING · sponsor: **Maastricht University Medical Center** · enrollment: 126 (estimated)

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** CP-506
- **DRUG:** Carboplatin
- **DRUG:** Immune checkpoint inhibitor

## Key facts

- **NCT ID:** NCT04954599
- **Lead sponsor:** Maastricht University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-30
- **Primary completion:** 2027-02
- **Final completion:** 2027-05
- **Target enrollment:** 126 (ESTIMATED)
- **Last updated:** 2025-10-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04954599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04954599, "Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04954599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*